ClinicalTrials.gg
RecruitingNCT03842475Updated Apr 19, 2023

Who Will Benefit From Bariatric Surgery for Diabetes?

An observational study in Diabetes Mellitus, Type 2 and Obesity, sponsored by Imperial College London. Recruiting at 1 site in United Kingdom. Open to participants aged 18 Years to 80 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-04-19.

Sponsored by Imperial College London · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Jan 2025, 1 year 10 months ago, but the record still lists the study as recruiting.
  • Started Oct 2018; still recruiting 8 years 1 month later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
210
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 19 studies in Diabetes Mellitus, Type 2 by Imperial College London — 7 open to participants now, 7 under way, none of them phase 3. Diabetes Mellitus, Type 2 · Imperial College London.

Started
2018
with 2 others
Observational
5 of 19
1 open now
Registered
12th of 19
by date

Among the 19 studies in Diabetes Mellitus, Type 2 by Imperial College London, this one is one of 3 that started in 2018, is one of 5 observational ones, and was the 12th registered.

Diabetes Mellitus, Type 2

10,403 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

7 of the 19 studies in Diabetes Mellitus, Type 2 by Imperial College London are open now, in 2 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 7 open studies →

Where they have run

Who these studies take

Of the 882 Diabetes Mellitus, Type 2 studies recruiting now, 372 (42%) set no upper age limit and 384 (44%) stop at 75 or younger; 52 take children under 18; 202 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 19 studies in Diabetes Mellitus, Type 2 by Imperial College London, or all of them as a file.
02

Study summary

A study investigating the influence of fat distribution, genetic susceptibility markers for type 2 diabetes (T2DM) and fat distribution, epigenetic and transcriptomic changes and gut hormone responses to a mixed meal on diabetes remission following bariatric surgery.

03

Conditions studied

  • Diabetes Mellitus, Type 2
  • Obesity
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Up to 150 patients recruited to completion from Imperial Weight Centre. Up to 60 healthy volunteers

Eligibility criteria

Bariatric surgery group

Inclusion Criteria:

  • Males and females planning to undergo RYGB
  • 18-80 years
  • Type 2 diabetes mellitus or prediabetes
  • Stable weight for at least 3 months
  • Obese ( ≥30kg/m2)
  • Eligible for surgery on the National Health Service (NHS) under The National Institute for Health and Care Excellence (NICE) 2014 criteria

Exclusion Criteria:

  • Current pregnancy
  • Inability to give
  • Type 1 diabetes
  • Low fasting C-peptide
  • Secondary diabetes or absence of β-cell function
  • Unable to undergo DEXA, cirrhosis, ascites, or other condition that may modify body fat composition e.g. underlying
  • Current smoker
  • Participation in another (interventional) trial within the last 3 months
  • Unable to understand English

Healthy volunteers

Inclusion criteria:

  • Aged 18-80 years
  • Male or female
  • Body mass index 19 - 25 kg/m2
  • Stable weight for at least three months

Exclusion criteria:

  • Abnormal glucose tolerance and fasting glucose
  • History of any medical, or other condition, or use of any medications, including over-the-counter products, which, in the opinion of the investigators, would either interfere with the study
  • Without access at home to a telephone, or other factor likely to interfere with ability to participate reliably in the study
  • Pregnancy or breastfeeding
  • Unable to maintain adequate for the duration of the study
  • Donated blood during the preceding 3 months or intention to do so before the end of the study
  • Current smoker
  • Participation in another trial within the last 3 months
  • Unable to understand English
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
210 participants (estimated)
Patient registry
No

Groups and cohorts

  • Surgical cohort

    Patients with type 2 diabetes undergoing Roux-en-Y gastric bypass surgery

    Procedure: Roux-en-Y gastric bypass (RYGB)

  • Control

    Healthy volunteers with normal body mass index

Interventions

  • ProcedureRoux-en-Y gastric bypass (RYGB)

    Bariatric surgery

06

What researchers measure

Primary outcomes

  1. Diabetes remission (partial or complete)

    Time frame: 1 year

  2. Diabetes remission (complete)

    Time frame: 1 year

Secondary outcomes

  1. Waist circumference, waist/hip ratio (cm)

    Time frame: 1 year

  2. Body mass index (kg/m2)

    Time frame: 1 year

  3. Weight loss

    Time frame: 1 year

  4. Change in visceral adipose tissue

    Dual Energy Xray Absorptiometry measurement (DEXA)

    Time frame: 1 year

  5. Change in visceral adipose tissue

    Magnetic resonance imaging (MRI) measurement

    Time frame: 1 year

  6. Change in ectopic fat

    MRI measurement

    Time frame: 1 year

Other outcomes

  1. Change in epigenetic data in tissues.

    Time frame: 1 year

  2. Changes in the transcriptome in tissues

    Time frame: 1 year

  3. Changes in gut hormone profiles

    Time frame: 1 year

  4. Histological scoring of specimens for Non-alcoholic fatty liver disease/Non-alcoholic steatohepatitis

    Time frame: 1 year

  5. Changes in gut microbiome

    Time frame: 1 year

07

Study locations

1 of 1 sites recruiting
  • Imperial College Healthcare NHS Trust
    London, Greater London W12 0HS, United Kingdom
    Recruiting
    • Julia S Kenkre, MB BChir · Contact
    • Tricia Tan, MB ChB · Principal investigator
08

References and documents

Publications

  • Kenkre JS, Ahmed AR, Purkayastha S, Malallah K, Bloom S, Blakemore AI, Prevost AT, Tan T. Who will benefit from bariatric surgery for diabetes? A protocol for an observational cohort study. BMJ Open. 2021 Feb 10;11(2):e042355. doi: 10.1136/bmjopen-2020-042355. PubMed 33568372 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2018 (actual). Primary completion is estimated for Jan 2025, 75 months after the start.

Of 436 non-industry observational studies under Diabetes Mellitus, Type 2, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 96. This study's planned 75 months is above that.

Counting every sponsor, half of 606 studies reached it within 32 months; a quarter within 17 and three quarters within 62.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 31, 2019
First posted
Feb 15, 2019
StartActual
Oct 1, 2018
Primary completionEst.
Jan 1, 2025
CompletionEst.
Oct 5, 2028
Last update
Apr 19, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 19, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03842475
Collaborators
National Institute for Health Research, United Kingdom
Responsible party
Sponsor
First posted
Feb 15, 2019
Start date
Oct 1, 2018
Primary completion
Jan 1, 2025 (estimated)
Completion
Oct 5, 2028 (estimated)
Last update
Apr 19, 2023

Study contacts

Julia S Kenkre, MB BChir
Contact
imperial.bariatricstudy@nhs.net
+44208383242
Tricia Tan, MB ChB
principal investigator · Imperial College London

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion